{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:38:27Z","timestamp":1793353107063,"version":"4.5.0"},"reference-count":130,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Rare Disease"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>This review explores enzyme replacement therapies (ERTs) for lysosomal storage diseases (LSDs), focusing on disease characteristics, mechanisms of action, clinical benefits, limitations, and implications for patient care and access. LSDs are a group of over 50 rare, inherited metabolic disorders caused by mutations affecting lysosomal enzymes, membrane proteins, or transporters. This leads to the accumulation of undegraded macromolecules in tissues such as the CNS (central nervous system), heart, and muscles, resulting in progressive dysfunction and possible death. ERTs, approved by FDA (U.S. Food and Drug Administration) and the EMA (European Medicines Agency), have been the cornerstone of treatment since 1995, significantly improving the patient\u2019s quality of life reducing organ damage and stabilizing cardiac and renal function. However, ERTs require lifelong intravenous infusions and have limited efficacy to treat CNS symptoms due to their inability to cross the BBB (blood\u2013brain barrier). Some patients develop immune responses known as ADA (anti-drug antibody), which can compromise treatment effectiveness. Emerging research into nanotechnology and combination therapies may help overcome these limitations. Newer formulations such as pegunigalsidase (Elfabrio\u00ae) use for FD (Fabry disease), exhibit lower affinity for developing ADA compared to other ERTs, offer reduced immunogenicity and safety profiles enhancement. Cost remains a major barrier, with annual treatment expenses often exceeding hundreds of thousands of dollars. Access to ERT is uneven, particularly in underfunded healthcare systems. In North America, reimbursement varies by region and payer, potentially delaying treatment and impacting outcomes. This review draws from MEDLINE, Cochrane Reviews, and PubMed (1984\u20132025) using search terms such as LSDs, ERTs, rare diseases, Gaucher disease, Fabry disease, and others. Ongoing research and health policy reforms are essential to improve access, equity, and therapeutic outcomes for patients with LSDs.<\/jats:p>","DOI":"10.1177\/26330040251405830","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T06:40:57Z","timestamp":1766558457000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Lysosomal storage diseases in North America: a comprehensive review of enzyme therapies and unmet needs"],"prefix":"10.1177","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2193-8837","authenticated-orcid":false,"given":"Lunawati L.","family":"Bennett","sequence":"first","affiliation":[{"name":"College of Pharmacy, Union University, 1050 Union University Drive, Jackson, TN 38305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121775"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00041.2009"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1590\/1678-4685-gmb-2018-0159"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2008.10.016"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2012.32"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0036-1"},{"key":"e_1_3_4_8_2","first-page":"118","article-title":"Lysosomal enzyme replacement therapies: historical development, clinical outcome, and future perspective","volume":"2017","author":"Solomon M","unstructured":"Solomon M, Muro S. Lysosomal enzyme replacement therapies: historical development, clinical outcome, and future perspective. Adv Drug Deliv Rev 2017; 118: 109\u2013134.","journal-title":"Adv Drug Deliv Rev"},{"key":"e_1_3_4_9_2","volume-title":"online metabolic and molecular bases of inherited disease","author":"Valle D","year":"2014","unstructured":"Valle D, Beaud AL, Vogelstein B, et al. The online metabolic and molecular bases of inherited disease. Part 16. Lysosomal Storage Disorder. New York: McGraw-Hill, 2014."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1590\/1678-4685-gmb-2016-0268"},{"key":"e_1_3_4_11_2","first-page":"983","volume-title":"Pediatric Endocrinol and Inborn Errors of Metabolism","author":"Giugliani R","unstructured":"Giugliani R, Vairo F, Beck M, et al. Lysosomal disorders. In: Sarafoglou K (eds.) Pediatric Endocrinol and Inborn Errors of Metabolism. 2nd ed. New York: McGraw-Hill Education, 2017: 983\u20131021.","edition":"2"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1148\/ryct.230154"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c09462"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00448"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom13081227"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom11040611"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/07388551.2016.1214557"},{"key":"e_1_3_4_18_2","article-title":"Nono-technology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease","volume":"13","author":"Abasolo I","year":"2020","unstructured":"Abasolo I, Seras-Franzoso, Molto-Abad M, et al. Nono-technology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease. Wiley Interdisp Rev Nanomed Nanobiotechnology 2020; 13: e1684.","journal-title":"Wiley Interdisp Rev Nanomed Nanobiotechnology"},{"key":"e_1_3_4_19_2","first-page":"132","article-title":"LSD- challenges, concepts and avenues for therapy: beyond rare diseases","author":"Marques ARA","year":"2019","unstructured":"Marques ARA, Saftig P. LSD- challenges, concepts and avenues for therapy: beyond rare diseases. J Cell Sci 2019; 132.","journal-title":"J Cell Sci"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00518-0"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108559"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aat5011"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom15030327"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-122313-085916"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.37"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09809-3"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/19768354.2022.2079719"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.32.786"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147699"},{"key":"e_1_3_4_30_2","first-page":"1189","volume-title":"Williams hematology","author":"Revel-Vilk S","unstructured":"Revel-Vilk S, Szer J, Zimran A. Gaucher disease and related lysosomal storage disease. In: Kaushansky K, Lichtman M, Prchal J, et al. (eds) Williams hematology, 10th ed. New York: McGraw-Hill, 2021: 1189\u20131202.","edition":"10"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.11.1281"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12235"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013500469"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.02.014"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712309105"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20190513"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.47162\/RJME.62.1.01"},{"key":"e_1_3_4_38_2","unstructured":"Fabrazyme \u00ae (agalsidase beta) [package insert] https:\/\/products.sanofi.us\/Fabrazyme\/Fabrazyme.pdf (accessed 1 February 2025)."},{"key":"e_1_3_4_39_2","unstructured":"Replagal \u00ae (agalsidase alfa) [package insert] https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/replagal-epar-product-information_en-0.pdf (accessed 1 February 2025)."},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047805"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2017-104863"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.07.009"},{"key":"e_1_3_4_43_2","article-title":"Safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with fabry disease: results from the phase 3, open-label, BRIGHT study","author":"Holida M.","year":"2022","unstructured":"Holida M. Safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with fabry disease: results from the phase 3, open-label, BRIGHT study. Presented at 7th Update on Fabry Disease. May 29\u201331, 2022.","journal-title":"Presented at 7th Update on Fabry Disease"},{"key":"e_1_3_4_44_2","unstructured":"Wallace E. Safety and Efficacy of Pegunigalsidase Alfa vs Agalsidase Beta on Renal Function in Fabry Disease: 24-Month Results from the Phase III Randomized Double-blind BALANCE Study Presented at 7th Update on Fabry Disease. May 29\u201331 2022."},{"key":"e_1_3_4_45_2","volume-title":"Presented at 7th Update on Fabry Disease","author":"West M.","unstructured":"West M. Switching from Agalsidase Alfa to Pegunigalsidase Alfa to Treat Patients with Fabry Disease: 1 Year of Treatment Data from BRIDGE, a Phase 3 Open-label Study. Presented at 7th Update on Fabry Disease. May 29-31, 2022."},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1266082"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1395287"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0655-y"},{"key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2147\/TCRM.S362871","article-title":"Monitoring and management of respiratory function in Pompe disease: current perspectives","volume":"9","author":"El Hadad","year":"2023","unstructured":"El Hadad, Khan M, Soufny R, et al. Monitoring and management of respiratory function in Pompe disease: current perspectives. Ther Clin Risk Manag 2023; 9: 713\u2013729.","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2014.04.010"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.05.29"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom10091339"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedneo.2013.03.009"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0412-3"},{"key":"e_1_3_4_55_2","unstructured":"Lumizyme \u00ae(alglucosides alfa) [packet insert] https:\/\/products.sanofi.us\/AlteredLumizyme\/lumizyme.pdf (accessed 1 February 2025)."},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2015.11.013"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-011-9404-7"},{"key":"e_1_3_4_58_2","article-title":"Outcome of patients with classical infantile Pompe disease receiving enzyme replacement therapy in German","author":"Hahn A","year":"2015","unstructured":"Hahn A, Praetorius S, Karrabul N. Outcome of patients with classical infantile Pompe disease receiving enzyme replacement therapy in German. JIMD Rep 2015.","journal-title":"JIMD Rep"},{"key":"e_1_3_4_59_2","first-page":"40","article-title":"Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing","author":"Bali DS","year":"2012","unstructured":"Bali DS, Goldstein JL, Banugaria S, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing. AJMG 2012; 160C: 40\u201349.","journal-title":"AJMG"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-014-9707-6"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01727"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-020-01080-y"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909859"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00241-6"},{"key":"e_1_3_4_65_2","unstructured":"QA with Sanofi: Nexviazyme Safely Aids Muscle Strength in LOPD https:\/\/pompediseasenews.com\/news\/nexviazyme-safely-aids-muscle-strength-late-onset-pompe-Sanofi-interview-question-answer\/ (accessed 1 February 2025)."},{"key":"e_1_3_4_66_2","first-page":"3551","volume-title":"The Metabolic & Molecular Basis on Inherited Disease","author":"Assman G","unstructured":"Assman G, Seedorf U. Acid lipase deficiency: Wolman disease and cholesteryl ester storage disease. In: Scriver CR, Beaud AL, Sly WS, Eds. The Metabolic & Molecular Basis on Inherited Disease, 8th ed. New York: McGraw-Hill Book Co., 2001: 3551\u20133572.","edition":"8"},{"key":"e_1_3_4_67_2","first-page":"282","article-title":"Generalized xanthomatosis with calcified adrenals","volume":"93","author":"Abramov A","year":"1956","unstructured":"Abramov A, Schorr S, Wolman M. Generalized xanthomatosis with calcified adrenals. AMA J Dis Child 1956; 93: 282\u2013286.","journal-title":"AMA J Dis Child"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2014.12.009"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0587-3"},{"key":"e_1_3_4_70_2","unstructured":"Kanuma \u00ae (Sebelipase alfa) [package insert] https:\/\/alexion.com\/Documents\/Kanuma_USPI.pdf (accessed February 2025)."},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.10.026"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.12.008"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.11.014"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jus.2009.06.001"},{"key":"e_1_3_4_75_2","unstructured":"Xenpozyme \u00ae (Olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations) https:\/\/www.xenpozyme.com (accessed 1 February 2025)."},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218055"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00620-8"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(18)30179-2"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.15250"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.14890"},{"key":"e_1_3_4_81_2","unstructured":"https:\/\/hcp.biomarin.com\/en-us\/brineura\/wp-content\/uploads\/sites\/2\/2022\/10\/Early-Diagnosis-brochure.pdf?v=0.5 (accessed 1 February 2025)"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19051500"},{"key":"e_1_3_4_83_2","article-title":"Long-term enzyme replacement therapy with Velmanase alfa (human recombinant alpha-mannosidase) slow disease progression in adult patients suffering from alpha-mannosidosis","volume":"120","author":"Borgwardt L","year":"2017","unstructured":"Borgwardt L, Lund AM, Amraoui Y. Long-term enzyme replacement therapy with Velmanase alfa (human recombinant alpha-mannosidase) slow disease progression in adult patients suffering from alpha-mannosidosis. Mol Genet Metab 2017; 120: S30.","journal-title":"Mol Genet Metab"},{"key":"e_1_3_4_84_2","unstructured":"Lamzede SMPC. Summary of product characteristics https:\/\/www.ema.europa.eu\/en\/Documents\/Product-information\/Lamzedeepar-product-information_en.pdf (accessed 1 February 2025)."},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2020.01011"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072515"},{"key":"e_1_3_4_87_2","unstructured":"Highlights of Prescribing information. https:\/\/products.sanofi.us\/Aldurazyme\/aldurazyme.pdf[packageinsert].Cambridge MA: BioMarin Pharmaceutical Inc (accessed 14 March 2023)."},{"key":"e_1_3_4_88_2","unstructured":"Nyhan WL Barhop BA Ozand P. Atlas of Metabolic Diseases. 2nd ed. Hunter disease mucopolysaccharidosis type II (MPSII)\/Iduronate sulfatase deficiency. Oxford University Press New York 2005. pp. 517\u2013523."},{"key":"e_1_3_4_89_2","author":"Scarpa M","unstructured":"Scarpa M, Lampe C. Mucopolysaccharidosis type II. Gene Reviews 2025.","journal-title":"Mucopolysaccharidosis type II"},{"key":"e_1_3_4_90_2","unstructured":"Elaprase\u00ae (Idursulfase) [package insert] https:\/\/www.elaprase.com\/Content\/pdf\/ELAPRASE%20PI.pdf (accessed June 2025)."},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1994.1132"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.11.007"},{"key":"e_1_3_4_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2018.02.002"},{"key":"e_1_3_4_94_2","doi-asserted-by":"publisher","DOI":"10.1038\/s10038-018-0534-8"},{"key":"e_1_3_4_95_2","unstructured":"Elosulfase alfa (Vimizim) [package Insert]. Novato CA. BioMarin Pharmaceutical Inc https:\/\/www.vimizim.com\/wp-content\/uploads\/2018\/02\/Prescribing-Information.pdf (accessed 1 February 2025)."},{"key":"e_1_3_4_96_2","first-page":"16","article-title":"Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities","volume":"241","author":"Puckett Y","year":"2021","unstructured":"Puckett Y, Mallorca-Hernandez A, Montano AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet J Rare Dis 2021; 241: 16.","journal-title":"Orphanet J Rare Dis"},{"key":"e_1_3_4_97_2","unstructured":"Naglazyme\u00ae (galsulfase) [package insert] https:\/\/www.naglazyme.com\/wp-content\/uploads\/2020\/09\/NaglazymePrescribingInformation.pdf (accessed 1 February 2025)."},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413456"},{"key":"e_1_3_4_99_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-018-0553-2"},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108145"},{"key":"e_1_3_4_101_2","first-page":"233","article-title":"Vestronidase alfa: a review in mucopolysaccharidosis VII","volume":"33","author":"McCafferty EH","year":"2019","unstructured":"McCafferty EH, Scott LJ. Vestronidase alfa: a review in mucopolysaccharidosis VII. Adis Drug Eval 2019; 33: 233\u2013240.","journal-title":"Adis Drug Eval"},{"key":"e_1_3_4_102_2","unstructured":"Mepsevii \u00ae (vestronidase alfa-vjbk) [package insert] https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761047s005lbl.pdf (accessed 1 February 2025)."},{"key":"e_1_3_4_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114234"},{"key":"e_1_3_4_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2024.108559"},{"key":"e_1_3_4_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107648"},{"key":"e_1_3_4_106_2","article-title":"Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease","volume":"13","author":"Abasolo I","year":"2020","unstructured":"Abasolo I, Seras-Franzoso J, Molto Abad M, et al. Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease. Wiley Interdisp Rev Nanomed Nanobiotechnology 2020; 13: e1684.","journal-title":"Wiley Interdisp Rev Nanomed Nanobiotechnology"},{"key":"e_1_3_4_107_2","article-title":"Prenatal delivery of enzyme replacement therapy to fetuses affected by early-onset lysosomal storage diseases","author":"Borges B","year":"2025","unstructured":"Borges B, Canepa E, Chang IJ, et al. Prenatal delivery of enzyme replacement therapy to fetuses affected by early-onset lysosomal storage diseases. AJMG 2025; Jan 31: e32132.","journal-title":"AJMG"},{"key":"e_1_3_4_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedhc.2017.04.016"},{"key":"e_1_3_4_109_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03754-1"},{"key":"e_1_3_4_110_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-017-0618-0"},{"key":"e_1_3_4_111_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310534"},{"key":"e_1_3_4_112_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-022-00369-w"},{"key":"e_1_3_4_113_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03492-4"},{"key":"e_1_3_4_114_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmd2.12403"},{"key":"e_1_3_4_115_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03416-2"},{"issue":"2","key":"e_1_3_4_116_2","first-page":"73","article-title":"Home therapy for lysosomal storage disorders: recommendations and guidelines","volume":"117","author":"Broomfield A","year":"2016","unstructured":"Broomfield A, Jones SA, Hughes DA, et al. Home therapy for lysosomal storage disorders: recommendations and guidelines. Mol Genet Metab 2016; 117(2): 73\u201378.","journal-title":"Mol Genet Metab"},{"key":"e_1_3_4_117_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2082200"},{"key":"e_1_3_4_118_2","first-page":"20","article-title":"The long-term impact of price controls in Medicare Part D","author":"Moreno G.","year":"2016","unstructured":"Moreno G. The long-term impact of price controls in Medicare Part D. Forum Health Econ Pol 2016; 20.","journal-title":"Forum Health Econ Pol"},{"key":"e_1_3_4_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2018.05.002"},{"key":"e_1_3_4_120_2","unstructured":"Rawson NSB. How might the choice of prescription drugs in provincial public insurance plans be impacted if a cost-control system like New Zealand\u2019s was adopted in Canada. Can Health Policy 2016."},{"key":"e_1_3_4_121_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-014-0108-6"},{"key":"e_1_3_4_122_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1420067"},{"key":"e_1_3_4_123_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11041067"},{"key":"e_1_3_4_124_2","first-page":"36","article-title":"Development of high sustained anti-drug antibody titers and corresponding clinical decline in late-onset Pompe disease patients after 11+ years on enzyme replacement therapy","volume":"13","author":"Kim KH","year":"2023","unstructured":"Kim KH, Desai AK, Vucko ER, et al. Development of high sustained anti-drug antibody titers and corresponding clinical decline in late-onset Pompe disease patients after 11+ years on enzyme replacement therapy. Mol Genet Metab Rep 2023; 13: 36.","journal-title":"Mol Genet Metab Rep"},{"key":"e_1_3_4_125_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom13091414"},{"key":"e_1_3_4_126_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2022.05.008"},{"key":"e_1_3_4_127_2","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13981"},{"key":"e_1_3_4_128_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-022-00738-7"},{"key":"e_1_3_4_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.06.028"},{"key":"e_1_3_4_130_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2025.109181"},{"key":"e_1_3_4_131_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1307558"}],"container-title":["Therapeutic Advances in Rare Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26330040251405830","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/26330040251405830","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26330040251405830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:10:53Z","timestamp":1777597853000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/26330040251405830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":130,"alternative-id":["10.1177\/26330040251405830"],"URL":"https:\/\/doi.org\/10.1177\/26330040251405830","relation":{},"ISSN":["2633-0040","2633-0040"],"issn-type":[{"value":"2633-0040","type":"print"},{"value":"2633-0040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"article-number":"26330040251405830"}}